- AN2 Therapeutics Inc filed plans on Friday to go public in an initial public offering in which it reportedly hopes to raise about $75 million.
- AN2 plans to list on the Nasdaq with the symbol of ANTX.
- The Menlo Park-based biotech is developing a therapy for non-tuberculous mycobacterial (NTM) lung disease, which typically attacks older people or those with a weakened immune system.
- See the IPO prospectus here.
- Its initial product candidate is epetraborole, a once-daily oral treatment for patients with NTM.
- The Company licensed exclusive worldwide development and commercialization rights for epetraborole from Anacor Pharmaceuticals, owned by Pfizer Inc (NYSE:PFE), in 2016.
- AN2 Therapeutics plans to conduct a Phase 2/3 trial in treatment-refractory Mycobacterium avium complex (MAC) lung disease, the most common type of NTM lung disease.
- The trial design is currently under review from the FDA, and the Company plans to initiate enrollment in the 1H22, with topline results for the Phase 2 part expected in mid-2023.
